The Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market revenue is expected to be worth US$ 3.3 billion in 2023, rising to US$ 6.2 billion by 2033. During the forecast period, the market is expected to grow at a CAGR of 6.6%.
Market expansion is being driven by growing enzyme deficits and lysosomal storage disorders such as Gaucher, Pompe, and Fabry. The market is expanding due to increased patient awareness of Pompe disease treatment. Furthermore, the growing prevalence of metabolic illnesses, dangerous body cells, and rare diseases is driving up demand for Gaucher and Pompe disease enzyme replacement therapy (ERT).
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771
Healthcare firms are working on enhanced enzyme replacement therapy therapies that will have an impact on market opportunities. Several life-threatening chronic disorders are boosting healthcare providers’ demand for Gaucher disease diagnosis. Furthermore, expanding economies, the medical tourism industry, and large investments are expanding market potential.
According to a National Fabry Foundation estimate, about 7,713 persons in the United States have Fabry disease in May 2020. Similarly, over 40,000 persons in the United States were diagnosed with Pompe disease in August 2021, according to a report from the National Institute of Neurological Disorders and Stroke.
High Treatment Costs Hamper the Market Growth
The availability of treatment resources for rare disorders is fueling market growth. Conversely, the increasing treatment and therapy costs and lack of skilled professionals limit the market growth. Moreover, the availability of alternative or low-cost solutions and therapies is restraining the market growth.
Key Takeaways:
- The enzyme replacement therapy (ERT) market for Gaucher and Pompe disorders is anticipated to be worth US$ 6.2 billion by 2033.
- The global market is growing at a CAGR of 6.6% over the predicted period.
- The US market is expected to account for 6.1% of the CAGR through 2033.
- During the projected period, the United Kingdom Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is expected to grow at a CAGR of 6.9%.
- Over the forecast period, the China market is expected to grow at a CAGR of 7.1%.
- By 2033, the Canadian market might grow at a 6.9% CAGR.
To remain ‘ahead’ of your competitors, Ask a Question@ https://www.futuremarketinsights.com/ask-question/rep-gb-12771
Who is Winning?
Key players focus on patients’ requirements and launching innovative products to improve their health. Research and development in advanced therapy treatment equipment for patients for a better quality of life with compelling results may drive market growth.
Players upsurge the market size through marketing methodologies, including agreements, collaborations, partnerships, product launches, mergers, and acquisitions.
Other Prominent Players in the Global Market:
- Alexion Pharmaceuticals, Inc.
- Pfizer
- BioMarin Pharmaceuticals Inc
- Ultragenyx Pharmaceutical Inc.
- Janssen Pharmaceuticals, Inc (J&J)
- Sigma-Tau Pharmaceuticals Inc,
- AbbVie Inc.
- Sanofi S.A.
- Shire Plc
- Merck KGaA
- Takeda Pharmaceuticals
Recent Developments in the Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market are:
- In November 2019, according to National Center for Biotechnology Information, Brineura launched enzyme replacement therapy for Neuronal Ceroid Lipofuscinosis Type 2 Disorder.
- In September 2021, Takeda Pharmaceutical Company partnered with JCR Pharmaceuticals Company for hunter syndrome treatment in the United States.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/12771
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market by Category
By Therapeutic Condition
- Gaucher Disease:
- Type 1 (Non-neuropathic)
- Type 2 (Acute Infantile Neuronopathic)
- Type 3 Gaucher Disease (Chronic Neuronopathic)
- Perinatal Lethal Gaucher Disease
- Cardiovascular Gaucher Disease:
- Pompe Disease
- Classic Infantile-onset
- Late-onset
By Route of Administration:
- Oral
- Parental
By Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
